Catalonia’s Life Sciences and Health Sector: A Rising European Powerhouse
Catalonia’s life sciences and health sector is experiencing robust and sustained growth, solidifying its position as a leading ecosystem in Europe. Recent data confirms a period of consistent expansion over the past 6-8 years, with key indicators pointing towards continued success.
Economic Impact and Growth
In 2025, the sector accounted for 7.6% of Catalonia’s GDP, making it the third-largest contributor to the regional economy, surpassed only by commerce and tourism. The industry generated €48.691 billion in revenue, an 8.8% increase compared to 2024, with the pharmaceutical industry representing 46% of that figure. This growth translated into 306,781 jobs, a 9% increase, representing 7.3% of Catalonia’s active workforce.
Small and medium-sized enterprises (SMEs) continue to dominate the landscape, comprising 90% of companies. While Barcelona remains the primary hub, accounting for 93% of businesses, a notable trend of territorial decentralization is emerging, with Girona gaining prominence.
International Trade and Investment
The BioRegion of Catalonia has regained its position as the leading exporter of healthcare products in Spain, surpassing Madrid after the latter benefited from COVID-19 vaccine sales. In 2024, Catalonia accounted for 45.7% of the country’s healthcare product exports, up from 41% the previous year. It also ranked as the second-largest importer, capturing 31% of the Spanish total.
Despite a slight decrease in absolute export and import values in 2024 – €9.165 billion and €9.403 billion respectively, down 2.5% and 3% from 2023 – the sector remains a significant player in international trade. Key export destinations include Switzerland, Germany and France, with pharmaceuticals being the most in-demand product.
Catalonia is also a magnet for foreign direct investment (FDI), attracting €2.382 billion between 2021 and 2025, with the majority (€1.574 billion) directed towards research and development. This investment has created 5,567 jobs.
A Hub for Innovation and Research
Catalonia is a strategic location for multinational corporations, hosting 79 production plants – 44% of the Spanish total. It concentrates nearly 50% of Spain’s pharmaceutical revenue and is home to 17 of the world’s top 20 pharma/medtech companies. Over 30 technology hubs dedicated to health have been established in the region between 2021 and 2025, generating or promising 8,000 jobs.
The region’s commitment to research is evident in its leading position in Europe for high-impact article publications, with 1,791 articles representing 52.8% of Spain’s total. Catalonia also ranks fourth in Europe and seventh globally in the number of active clinical trials, with 5,768 trials representing 92% of those with Spanish participation.
Startup Ecosystem and Funding
Investment in Catalan startups and scaleups in the life sciences and health sector reached a record high of €517 million in 2025. Venture capital remains the primary funding source (€327.6 million), but grants have seen significant growth, doubling from €60 million to €124.3 million. Since 2016, 639 new startups have been created in the BioRegion, with 464 remaining active. The rate of startup creation is approximately one per week, and spin-offs are established at a rate of one per month.
Future Trends and Opportunities
The continued growth of Catalonia’s life sciences and health sector is underpinned by several key factors, including a strong clinical capacity, competitive research facilities, supportive government policies, and a highly skilled workforce. The region’s ability to attract and retain talent, with over 26,000 annual graduates in scientific fields and more than 18,000 research professionals (nearly half of whom are women), will be crucial for sustaining this momentum.
FAQ
Q: What percentage of Catalonia’s GDP does the life sciences and health sector represent?
A: 7.6% as of 2025.
Q: What is the primary driver of growth in the sector?
A: The pharmaceutical industry, which accounts for 46% of the sector’s revenue.
Q: Where is most of the activity concentrated?
A: While Barcelona remains the primary hub, there is a growing trend of decentralization, with Girona gaining prominence.
Q: How does Catalonia compare to other regions in terms of clinical trials?
A: Catalonia ranks fourth in Europe and seventh globally in the number of active clinical trials.
Did you know? Catalonia is home to nearly 50% of Spain’s pharmaceutical revenue.
Pro Tip: Keep an eye on Girona as an emerging hub for life sciences innovation within Catalonia.
Explore more articles on Catalonia’s economic landscape and European biotech hubs.
Subscribe to our newsletter for the latest updates on the life sciences and health sector!
Keep reading